Emerging studies suggested that the NRP2/WDFY1 axis was required to maintain endocytic activity in cancer cells, and therefore, therapeutic targeting of endocytosis may be an attractive strategy to selectively target cancer cells in a variety of malignancies (88). The gene discussed is NRP2; the disease is cancer.